Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02244489 · ClinicalTrials.gov registry record · Phase 1
Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 1 study, sponsored by Sierra Oncology LLC - a GSK company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02244489 is a Phase 1 study that was terminated before completion, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 16 participants.
The verdict
NCT02244489, a Phase 1 study, was terminated before completion, sponsored by Sierra Oncology LLC - a GSK company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma.
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG Momelotinib (MMB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-11-05 |
| Est. Completion | 2017-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02244489
The ClinicalTrials.gov registry entry for NCT02244489 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sierra Oncology LLC - a GSK company, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT02244489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02244489 about?
NCT02244489 is a clinical study titled "Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma". This study will evaluate the safety, tolerability, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma.
What is the current status of trial NCT02244489?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-11-05. Estimated completion is 2017-04-05.
What interventions are being tested in trial NCT02244489?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), Momelotinib (MMB) (DRUG).
Who is sponsoring clinical trial NCT02244489?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.